Literature DB >> 23553125

The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey.

Serdar Berk1, Huseyin Yalcin, Omer Tamer Dogan, Kursat Epozturk, Ibrahim Akkurt, Zehra Seyfikli.   

Abstract

One of the most significant diseases related to environmental asbestos exposure is malignant mesothelioma (MM). Sivas province is located in the Central Anatolia where asbestos exposure is common. We aimed to study clinical, demographical and epidemiologic features of the patients with MM in Sivas, along with the history of asbestos exposure. In total, 219 patients with MM who were diagnosed in our hospital between 1993 and 2010 were retrospectively analyzed in terms of demographical and clinical features. Rock, soil and house plaster samples were taken from the habitats of those patients and were evaluated with optical microscopy and X-ray diffraction methods. The age of the patients ranged between 18 and 85 years. The male-to-female ratio was 1.4:1. Most of the patients confirmed an asbestos exposure history. The most frequent symptoms of the patients were chest pain (60 %) and dyspnea (50 %). The gap between the start of first symptoms and the diagnosis date was approximately 4 months in average. The plaster materials used in most of the houses were made up of mainly carbonate and silicate minerals and some chrysotile. Ophiolitic units contained fibrous minerals such as serpentine (clino + orthochrysotile) chiefly and pectolite, brucite, hydrotalcite and tremolite/actinolite in smaller amounts. MM is not primarily related to occupational asbestos exposure in our region, and hence, environmental asbestos exposure may be indicted. Yet, single or combined roles and/or interactions of other fibrous and non-fibrous minerals in the etiology of MM are not yet fully understood and remain to be investigated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23553125     DOI: 10.1007/s10653-013-9518-y

Source DB:  PubMed          Journal:  Environ Geochem Health        ISSN: 0269-4042            Impact factor:   4.609


  23 in total

1.  Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province.

Authors:  J C WAGNER; C A SLEGGS; P MARCHAND
Journal:  Br J Ind Med       Date:  1960-10

Review 2.  Chrysotile as a cause of mesothelioma: an assessment based on epidemiology.

Authors:  Charles M Yarborough
Journal:  Crit Rev Toxicol       Date:  2006-02       Impact factor: 5.635

3.  Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.

Authors:  Selma Metintas; Muzaffer Metintas; Irfan Ucgun; Ulku Oner
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

4.  An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos.

Authors:  Y I Baris; N Bilir; M Artvinli; A A Sahin; F Kalyoncu; P Sebastien
Journal:  Br J Ind Med       Date:  1988-12

Review 5.  Short, thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence.

Authors:  Yasunosuke Suzuki; Steven R Yuen; Richard Ashley
Journal:  Int J Hyg Environ Health       Date:  2005       Impact factor: 5.840

Review 6.  The pathogenesis of mesothelioma.

Authors:  Michele Carbone; Robert A Kratzke; Joseph R Testa
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

Review 7.  Peritoneal mesothelioma: a review.

Authors:  Alessio Bridda; Ilaria Padoan; Roberto Mencarelli; Mauro Frego
Journal:  MedGenMed       Date:  2007-05-10

Review 8.  Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.

Authors:  Shoshana J Weiner; Siyamek Neragi-Miandoab
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-12       Impact factor: 4.553

Review 9.  Mesothelioma of childhood.

Authors:  A E Fraire; S Cooper; S D Greenberg; P Buffler; C Langston
Journal:  Cancer       Date:  1988-08-15       Impact factor: 6.860

Review 10.  Malignant mesothelioma.

Authors:  Alastair J Moore; Robert J Parker; John Wiggins
Journal:  Orphanet J Rare Dis       Date:  2008-12-19       Impact factor: 4.123

View more
  5 in total

1.  Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.

Authors:  Mehmet Bayram; Isa Dongel; Ali Akbaş; Ismail Benli; Muhammed Emin Akkoyunlu; Nur Dilek Bakan
Journal:  Lung       Date:  2013-10-30       Impact factor: 2.584

2.  Estimating the incidence of malignant mesothelioma in Vietnam: a pilot descriptive cancer registration study.

Authors:  Matthew J Soeberg; Mai Anh Luong; Van Thuan Tran; Anh Thanh Tran; Thị Thu Huyen Nguyen; Dieu Bui; Thi Hoai Nga Nguyen; Ken Takahashi; Nico van Zandwijk
Journal:  Int J Occup Environ Health       Date:  2016-07-08

3.  The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure.

Authors:  Alessandro Marinaccio; Marisa Corfiati; Alessandra Binazzi; Davide Di Marzio; Alberto Scarselli; Pierpaolo Ferrante; Michela Bonafede; Marina Verardo; Dario Mirabelli; Valerio Gennaro; Carolina Mensi; Gert Schallemberg; Guido Mazzoleni; Enzo Merler; Paolo Girardi; Corrado Negro; Flavia D'Agostin; Antonio Romanelli; Elisabetta Chellini; Stefano Silvestri; Cristiana Pascucci; Roberto Calisti; Fabrizio Stracci; Elisa Romeo; Valeria Ascoli; Luana Trafficante; Francesco Carrozza; Italo Francesco Angelillo; Domenica Cavone; Gabriella Cauzillo; Federico Tallarigo; Rosario Tumino; Massimo Melis; Sergio Iavicoli
Journal:  Occup Environ Med       Date:  2017-12-21       Impact factor: 4.402

Review 4.  HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.

Authors:  Yanbin Wang; Zhaoqiang Jiang; Jianing Yan; Shibo Ying
Journal:  Dis Markers       Date:  2019-02-12       Impact factor: 3.434

5.  Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos.

Authors:  İsa Döngel; Ali Akbaş; İsmail Benli; Mehmet Bayram
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-06-28       Impact factor: 0.332

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.